Will Depo-Provera Lower Testosterone in a Woman with Already Low Testosterone?
Yes, Depo-Provera (depot medroxyprogesterone acetate) will likely further lower testosterone levels in a woman who already has markedly low testosterone. This is a significant concern that should influence your contraceptive counseling.
Evidence from Research Studies
The research evidence consistently demonstrates that DMPA suppresses androgen levels in women:
A 2012 prospective study found that DMPA-SC caused statistically significant decreases in total testosterone and androstenedione levels by week 26 across all body weight categories 1. This effect was consistent regardless of baseline BMI.
Multiple studies in women with polycystic ovary syndrome (who typically have elevated androgens) showed that medroxyprogesterone acetate significantly suppressed testosterone levels 2, 3, 4. One study documented testosterone decreases of approximately 60% during MPA therapy 4.
The mechanism involves suppression of sex hormone-binding globulin (SHBG), which can paradoxically increase free testosterone fraction even as total testosterone falls 2. However, in women with already low testosterone, this mechanism offers no protective benefit.
Clinical Implications for Your Patient
In a woman in her 30s with markedly low baseline testosterone, administering Depo-Provera poses several risks:
Further suppression of already deficient testosterone levels could worsen symptoms potentially related to androgen deficiency (though the Endocrine Society guidelines note there is no well-defined androgen deficiency syndrome in women) 5
The testosterone-lowering effect persists throughout the duration of DMPA action (approximately 12-13 weeks per injection) 1, 3
Recovery after discontinuation occurs within weeks to months, but this means prolonged exposure to even lower testosterone levels during active use 3
Recommendation
Consider alternative contraceptive methods that do not suppress the hypothalamic-pituitary-gonadal axis. Options include:
- Copper IUD (no hormonal effects)
- Barrier methods
- Progestin-only methods with less systemic absorption (levonorgestrel IUD)
If Depo-Provera is strongly preferred or other options are contraindicated, counsel the patient about:
- Expected further decline in testosterone levels
- Potential worsening of symptoms that may be androgen-related (though causality is uncertain per guidelines 5)
- The lack of approved testosterone therapy for women outside of specific research contexts 5
Important Caveat
The Endocrine Society explicitly states that there is currently no well-defined clinical syndrome of androgen deficiency in women, and they recommend against making this diagnosis 5. However, the biochemical effect of DMPA lowering testosterone is well-established, and the clinical significance in a woman with already low levels remains uncertain but potentially concerning.